media – Page 4 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Grand Pharmaceutical’s Class 1 innovative traditional Chinese medicine drug GPN01360 has reached its clinical endpoint in the Phase II clinical trial in China

On December 8, Grand Pharmaceutical (00512) issued an announcement stating that the Group’s traditional Chinese medicine…Class 1 innovative drugsThe Phase II clinical trial of GPN01360 in China successfully met its clinical endpoint. This study enrolled 148 patients with depression, who received oral administration for 8 weeks. The primary assessment was the efficacy and safety of GPN01360 compared to placebo in treating depression. Results showed that the primary efficacy endpoint, the change from baseline on the Hamilton Depression Rating Scale (HAMD-17), was significantly different from placebo (P=0.0006<0.05). Secondary efficacy endpoints, such as the Montgomery-Asperger’s Depression Rating Scale (MADRS), also showed significant differences (P<0.05). Furthermore, GPN01360 demonstrated good safety and tolerability, with no significant toxic side effects observed. GPN01360 is a Class 1.1 innovative traditional Chinese medicine 　　for the treatment of depression . Its main ingredients include 12 herbs such as Bupleurum, Curcuma longa, and Citrus medica , which have the effects ...
- Source: drugdu
- 62
- December 9, 2025
Incyte Pharma Drug Shows Positive Effect in Treatment of a Certain Type of Blood Cancer

Incyte Pharma states new clinical data shows its monoclonal antibody drug INCA033989 can rapidly and significantly reduce spleen volume, alleviate associated symptoms, and improve anemia in patients with myelofibrosis who have a specific genetic mutation. The preliminary research results come from treating patients with CALR mutation (mutCALR) myelofibrosis with the drug as monotherapy and in combination with ruxolitinib. The drug demonstrated good safety, with no dose-limiting toxicities reported. Incyte Pharma plans to initiate a registration program for myelofibrosis treatment in 2026. https://finance.eastmoney.com/a/202512073584646874.html
- Source: drugdu
- 52
- December 9, 2025
Ophthalmic preparation GB10 injection receives clinical trial approval notice

Securities Daily Online News On the evening of December 8th, Sinovac Pharmaceutical issued an announcement stating that its wholly-owned subsidiary, Shenzhen Sinovac Pharmaceutical Co., Ltd., recently received a “Notice of Drug Clinical Trial Approval” from the National Medical Products Administration (NMPA). The NMPA has approved Shenzhen Sinovac to carry out clinical trials for the “GB10 Injection”. https://finance.eastmoney.com/a/202512083585556010.html
- Source: drugdu
- 52
- December 9, 2025
Huadong Medicine enters commercialization partnership with Sinorda Pharma

China Securities Journal, China Securities Network (Reporter Fu Suying) – On December 7, Huadong Medicine’s wholly-owned subsidiary Huadong Medicine (Hangzhou) Co., Ltd. announced that it has entered into an exclusive commercialization partnership for mainland China with Guizhou Sinorda Biotech Co., Ltd. and its wholly-owned subsidiaries Shanghai Sinorda Pharmaceutical Technology Co., Ltd. and Jiangsu Taris Sinorda Biopharmaceutical Co., Ltd. (collectively referred to as “Sinorda Pharma”). The partnership covers Sinorda’s product Linaprazan Glutarate Capsules and other dosage forms. Linaprazan is a next-generation potassium-competitive acid blocker (P-CAB) drug co-developed by Sinorda Pharma and Cinclus Pharma for the treatment of digestive system diseases. Leveraging Huadong Medicine’s strong commercialization platform, Linaprazan is expected to achieve rapid market uptake and will further enhance Huadong Medicine’s product portfolio in the digestive disease field. On December 7, the National Healthcare Security Administration disclosed that Linaprazan, indicated for gastroesophageal reflux disease, and the PARP inhibitor Senaparib (Paisuning®) have been ...
- Source: drugdu
- 50
- December 9, 2025
Changchun High & New Tech’s Two Drugs from Controlled Subsidiaries Added to National Reimbursement Drug List

Changchun High & New Tech (000661) announced on the evening of December 8 that, according to the National Drug Reimbursement List for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2025) (Medical Insurance Notice [2025] No. 33, hereinafter referred to as the “National Reimbursement Drug List”) jointly issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, two drugs from the company’s controlling subsidiary, Changchun GeneScience Pharmaceuticals Co., Ltd. (hereinafter referred to as “GeneScience Pharma”), have been newly included in the National Reimbursement Drug List. These are Jinsaizeng (currently the generic name is “Jinpei Growth Hormone Injection”), which was independently developed by GeneScience Pharma, and Meishiya (generic name: “Megestrol Acetate Oral Suspension”), which was introduced through cooperation. It is reported that Jinsaizeng is the world’s first long-acting growth hormone approved for market by GeneScience Pharma in January 2014. Its currently approved indications include: ...
- Source: drugdu
- 60
- December 9, 2025
Chinese-made ADCs stun the field once again

The ESMO-Asia (European Society for Medical Oncology Asian Congress) will be held in Singapore from December 5-7, 2025. At ESMO-Asia, Baili Tianheng presented clinical data for the first time on its next-generation HER2 ADC drug T-Bren (BL-M07D1) for the treatment of HER2-mutant non-small cell lung cancer. The study results show that T-Bren has excellent efficacy and outstanding safety in treating HER2-mutant lung cancer, and is expected to become the best-in-class HER2 ADC. Patients with HER2-mutant lung cancer have long faced treatment challenges. HER2 mutations account for approximately 2%-4% of non-small cell lung cancer patients, and are more common in non-smokers, women, and patients with lung adenocarcinoma. However, the objective response rate of chemotherapy for this disease is only 30%, and the median progression-free survival is about 6 months. Immunotherapy monotherapy and combination therapy have limited efficacy, with first-line combination therapy resulting in a PFS of only 5-10 months. Therefore, HER2 ...
- Source: drugdu
- 52
- December 9, 2025
Vaccination should be expanded from children to the entire life cycle population

In 2021, the influenza vaccination rate among adults aged 18-59 in China was only 0.52%, and the vaccination rates for pneumonia and influenza among chronic patients such as chronic obstructive pulmonary disease are also worrying. “On December 5th, Liang Wannian, a professor at Tsinghua University and dean of the School of General Medicine at Southern University of Science and Technology, stated at the adult vaccine consensus conference and special seminar that challenges such as insufficient accessibility and convenience of vaccination services, high costs, and vaccine hesitancy continue to increase the risk of illness among adults, exacerbating the burden on families, society, and medical service systems. “China has made remarkable achievements in children’s immunization planning, but adult immunization faces weaknesses.” Yin Zundong, a researcher at the Immunization Planning Center of the China Center for Disease Control and Prevention, said that in the context of population aging, infectious diseases such as ...
- Source: drugdu
- 57
- December 9, 2025
TEBAO Biotech’s Yipeisheng is included in medical insurance to realize clinical value through differentiated innovation

On December 7th, according to Zhongzheng News and Zhongzheng Network (Wang Luo), the long-acting growth hormone – Yipei Growth Hormone Injection (trade name: Yipei Sheng) independently developed by Tebao Biotechnology ®） Successfully included in the medical insurance catalog through negotiation. This entry into medical insurance has profound significance for TeBao Biotechnology. It not only marks the product’s qualification for national market access, but also verifies a core business proposition in the context of medical insurance negotiations: differentiated innovative drugs with significant clinical advantages and higher safety can only gain recognition and support. Yi Peisheng ® The smooth entry into the market is due to its solid “quality hard power”, especially its breakthrough innovation and safety upgrade in molecular design, which has built a differentiation advantage that is difficult to replicate for the product. In the field of pediatric medication, the ability to achieve higher “safety” through technological means is ...
- Source: drugdu
- 57
- December 9, 2025
CPhI North America

Organiser：Informa Markets Time： June 2nd – 4th, 2026 Address：1101 Arch Street Philadelphia, PA 19107, Philadelphia, PA, United States Exhibition hall：Pennsylvania Convention Center, Philadelphia Product range: Active Pharmaceutical Ingredients (API): Vitamins, hormones, sulfonamides, antipyretic analgesics, tetracyclines, amino acids and their derivatives, chloramphenicols, digestive system medications, other anti-infective agents, penicillins, aminoglycosides, lincomycins, cardiovascular system medications, anti-parasitic drugs, cephalosporins, macrolides, respiratory system medications, central nervous system medications, and other Western pharmaceutical ingredients. Packaging Equipment: Pharmaceutical machinery, packaging machinery, packaging materials, pharmaceutical production equipment and technology, pharmaceutical packaging equipment, pharmaceutical packaging materials, pharmaceutical production, sterilization and dispensing systems, and laboratory instrumentation. Pharmaceutical Products: Various traditional Chinese patent medicines, Western medicines, new drugs, various APIs, chemical pharmaceuticals, pharmaceutical intermediates, biopharmaceuticals, traditional medicines, Chinese herbal medicines, herbal extracts, animal and plant extracts, veterinary drugs, food ingredients and additives, etc. About CPhI North America： CPhI North America, the United States World Pharmaceutical Ingredients Exhibition, is ...
- Source: drugdu
- 56
- December 9, 2025
Conbercept ophthalmic injection included in medical insurance catalog

December 8th, Yasuhiro Pharmaceuticals(002773) issued an announcement stating that Conbercept ophthalmic injection has been included in the “National Basic Medical Insurance” .The drug is listed as a Category B drug in the ” National Respiratory Health Insurance and Work Injury Insurance Drug Catalog (2025)”. This decision, issued by the National Healthcare Security Administration on December 7, 2025, signifies official recognition of the drug’s importance in the treatment of retinal diseases. Conbercept ophthalmic injection is currently the only domestically produced innovative drug in the catalog that covers all four major indications for fundus diseases.The company stated that inclusion in the national medical insurance catalog will improve the stability and accessibility of medication for patients. Simultaneously, the company is actively conducting Phase III clinical trials of its high-dose version of Conbercept, as well as clinical trials of gene therapy drugs KH631 and KH658 in both China and the United States. The new ...
- Source: drugdu
- 61
- December 8, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.